Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD?
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Brat (Brno, Czech Republic), M. Plutinsky (Brno, Czech Republic), V. Koblizek (Hradec Kralove, Czech Republic), J. Zatloukal (Olomouc, Czech Republic), P. Popelkova (Ostrava, Czech Republic), T. Dvorak (Mlada Boleslav, Czech Republic), P. Safranek (Pilsen, Czech Republic), D. Rakita (Prague, Czech Republic), P. Vanik (Ceske Budejovice, Czech Republic), Z. Liptakova (Ceske Budejovice, Czech Republic), L. Heribanova (Prague, Czech Republic), P. Musilova (Jihlava, Czech Republic), M. Sipkova (Liberec, Czech Republic), E. Kocova (Hradec Kralove, Czech Republic), B. Novotna (Prague, Czech Republic), O. Kudela (Hradec Kralove, Czech Republic), M. Kopecky (Hradec Kralove, Czech Republic), K. Neumannova (Olomouc, Czech Republic), M. Svoboda (Brno, Czech Republic), J. Jarkovsky (Brno, Czech Republic), Z. Zbozinkova (Brno, Czech Republic), J. Svancara (Brno, Czech Republic), J. Lnenicka (Usti nad Labem, Czech Republic), V. Rihak (Zlin, Czech Republic). Cluster phenotyping as an approach to identify COPD patients at risk of poor prognosis.. 3853

Member's Comments

No comment yet.

Related content which might interest you: COPD detected with screening: impact on patient management and prognosis Source: Eur Respir J 2014; 44: 1571-1578 Year: 2014 Readmission in COPD patients: should we consider it a marker of quality of care or a marker of a more severe disease with a worse prognosis? Source: Eur Respir J 2016; 48: 279-281 Year: 2016 Clinical phenotyping of COPD patients: a simple tool with prognosis value Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond Year: 2018 Readmission in COPD patients: should we consider it a marker of quality of care or a marker of a more severe disease with a worse prognosis? Source: Eur Respir J 2016; 48: 281-282 Year: 2016 Cluster analysis identifying patients with COPD at high-risk of 2-year mortality: preliminary results. Source: International Congress 2017 – Assessing the functional status of patients with COPD Year: 2017 COPD: implementing biomarkers to improve prognosis Source: Virtual Congress 2021 – Clinical year in review Year: 2021 Detecting undiagnosed COPD: Using routine primary care data to select and validate candidate variables for COPD risk prediction Source: Annual Congress 2013 –Early diagnosis and effectiveness of disease management in primary care Year: 2013 Introducing a new prognostic instrument for long-term mortality prediction among COPD patients - the CADOT index. Source: International Congress 2019 – Advances in clinical management of COPD Year: 2019 Preselection of patients at high risk for COPD by simple screening questions Source: Annual Congress 2008 - COPD - clinical and epidemiological aspects Year: 2008 Cluster analysis identifies distinct clinical phenotypes with poor treatment responsiveness in asthma. Source: International Congress 2018 – Asthma: clinical screening tools Year: 2018 COPD screening and risk factor frequency identification study Source: Annual Congress 2013 –Disease control and quality of life in airway diseases Year: 2013 Identifying COPD patients at risk for worse symptoms, quality of life and self-efficacy: A cluster analysis Source: International Congress 2017 – Assessing the functional status of patients with COPD Year: 2017 Identification of clinical phenotypes using cluster analyses in COPD patients Source: International Congress 2019 – Phenotypes and comorbidities of airway diseases Year: 2019 Pilot: identification of rehospitalization risk factors for patients with COPD Source: Annual Congress 2005 - Assessment and intervention from primary care centre to hospital Year: 2005 Predicting risk of undiagnosed COPD: development and validation of the TargetCOPD score Source: Eur Respir J, 49 (6) 1602191; 10.1183/13993003.02191-2016 Year: 2017 IPF cluster analysis highlights diagnostic delay and cardiovascular comorbidities association with outcome Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Developing a claims’-based algorithm to identify US patients with COPD Source: International Congress 2019 – More and more COPD Year: 2019 Mortality risk prediction in COPD by a prognostic biomarker panel Source: Eur Respir J 2014; 44: 1557-1570 Year: 2014 Will the population ²at risk for COPD² develop COPD? Source: Eur Respir J 2005; 26: Suppl. 49, 218s Year: 2005 Identification of clinical phenotypes in patients with and without COPD using cluster analysis Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities Year: 2016